Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Jul:249:86-97.
doi: 10.1016/j.ahj.2022.04.001. Epub 2022 Apr 8.

Discontinuing vs continuing ACEIs and ARBs in hospitalized patients with COVID-19 according to disease severity: Insights from the BRACE CORONA trial

Ariane Vieira Scarlatelli Macedo  1 , Pedro Gabriel Melo de Barros E Silva  2 , Thiago Ceccatto de Paula  3 , Renata Junqueira Moll-Bernardes  4 , Tiago Mendonça Dos Santos  5 , Lilian Mazza  6 , Andre Feldman  7 , Guilherme D Andréa Saba Arruda  8 , Denílson Campos de Albuquerque  9 , Andrea Silvestre de Sousa  10 , Olga Ferreira de Souza  11 , C Michael Gibson  12 , Christopher B Granger  13 , John H Alexander  13 , Renato D Lopes  14
Affiliations
Randomized Controlled Trial

Discontinuing vs continuing ACEIs and ARBs in hospitalized patients with COVID-19 according to disease severity: Insights from the BRACE CORONA trial

Ariane Vieira Scarlatelli Macedo et al. Am Heart J. 2022 Jul.

Abstract

Background: We explored the effect of discontinuing versus continuing angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) on clinical outcomes in patients with COVID-19 according to baseline disease severity.

Methods: We randomized 659 patients with a confirmed diagnosis of COVID-19 and classified them as having mild or moderate COVID-19 disease severity at hospital presentation using blood oxygen saturation and lung imaging. The primary outcome was the mean ratio of number of days alive and out of the hospital at 30 days according to disease severity.

Results: At presentation, 376 patients (57.1%) had mild and 283 (42.9%) had moderate COVID-19. In patients with mild disease, there was no significant difference in the number of days alive and out of the hospital between ACEI/ARB discontinuation (mean 23.5 [SD 6.3] days) and continuation (mean 23.8 [SD 6.5] days), with a mean ratio of 0.98 (95% CI 0.92-1.04). However, in patients with moderate disease, there were fewer days alive and out of the hospital with ACEI/ARB discontinuation (mean 19.6 [SD 9.5] days) than continuation (mean 21.6 [SD 7.6] days), with a mean ratio of 0.90 (95% CI 0.81-1.00; P-interaction = .01). The impact of discontinuing versus continuing ACEIs/ARBs on days alive and out of hospital through 30 days differed according to baseline COVID-19 disease severity.

Conclusions: Unlike patients with mild disease, patients with moderate disease who continued ACEIs/ARBs had more days alive and out of hospital through 30 days than those who discontinued ACEIs/ARBs. This suggests that ACEIs/ARBs should be continued for patients with moderate COVID-19 disease severity.

Clinical trial registration: ClinicalTrials.gov (NCT04364893).

PubMed Disclaimer

Figures

Figure 1
Figure 1
A, Primary outcome: days alive and out of the hospital at 30 days in patients with mild disease severity at presentation. B, Primary outcome: days alive and out of the hospital at 30 days in patients with moderate disease severity at presentation
Figure 2
Figure 2
Secondary outcomes according to disease severity at presentation in the intention to treat population.
See this image and copyright information in PMC

References

    1. Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584:430–436. - PMC - PubMed
    1. Gao C, Cai Y, Zhang K, et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J. 2020;41:2058–2066. - PMC - PubMed
    1. Drager LF, Pio-Abreu A, Lopes RD, et al. Is Hypertension a Real Risk Factor for Poor Prognosis in the COVID-19 Pandemic? Curr Hypertens Rep. 2020;22:43. - PMC - PubMed
    1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–1242. - PubMed
    1. Mancia G, Rea F, Ludergnani M, et al. Renin–angiotensin–aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020;382:2431–2440. - PMC - PubMed

Publication types

Substances

Associated data